title: [Clinical and fundamental studies on intravenous drip infusion of gentamicin in the pediatric field. Pediatric study group of gentamicin].
abstract: A multiclinic study of gentamicin (GM) given by intravenous drip infusion was carried out by the Gentamicin Pediatric Study Group. The results are summarized as follows: 1. Upon intravenous drip infusion of GM at a dose range of 2.0-2.5 mg/kg over a period of 0.5-1 hour, therapeutically effective serum concentrations of 4-12 micrograms/ml were obtained. These values are similar to reported values in previous studies using GM intramuscular injection. 2. High urinary concentrations were observed up to 6 hours after administration, and the urinary recovery rate was approximately 60%. 3. Of a total of 142 cases collected, 117 cases were evaluated. Efficacy rates by diseases were: 100% in pneumonia (30/30), 98.3% in urinary tract infections (59/60), and 92.3% in other infections (skin and soft tissue) (12/13), with an overall efficacy rate of 94.9% (including 77 "excellent" cases). 4. Bacteriological examinations showed high eradication rates with the use of GM; i.e., 80% with Staphylococcus aureus (8/10), 60% with Pseudomonas aeruginosa (3/5), 100% with Haemophilus influenzae (7/7) and 97.8% with Escherichia coli (44/45), achieving an overall eradication rate of 92.4%. In mixed infections, the eradication rate was 85.7% (6/7). 5. No ototoxicity, nephrotoxicity or allergic reactions was observed. Abnormal laboratory findings observed were: GOT elevation in 3.1% of cases, GPT elevation in 3.9%, platelet increase in 1.5% and eosinophil increase in 0.8%, thus an overall rate of the appearance of abnormality was 5.6%. The above results indicate that an intravenous drip infusion of GM is a useful method for treating infections in pediatrics.
authors.affiliation: Department of Infectious Disease, National Children's hospital.
authors.forename: Y
authors.initials: Y
authors.lastname: Ichihashi
authors.forename: M
authors.initials: M
authors.lastname: Hori
authors.forename: O
authors.initials: O
authors.lastname: Tatsuzawa
authors.forename: N
authors.initials: N
authors.lastname: Okabe
authors.forename: H
authors.initials: H
authors.lastname: Wakasugi
authors.forename: H
authors.initials: H
authors.lastname: Yoshioka
authors.forename: K
authors.initials: K
authors.lastname: Fujita
authors.forename: H
authors.initials: H
authors.lastname: Sakata
authors.forename: C
authors.initials: C
authors.lastname: Ishida
authors.forename: H
authors.initials: H
authors.lastname: Kakehashi
mesh_terms: D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008297:Male
chemical_list: D005839:Gentamicins